BASEL, Switzerland,
March 5, 2019 /PRNewswire/ -- Myovant
Sciences (NYSE: MYOV), a leading clinical-stage
biopharmaceutical company focused on women's health and endocrine
diseases, today announced that Lynn
Seely, M.D., President and Chief Executive Officer, will
present at the following investor conferences:
- Cowen and Company 39th Annual Health Care
Conference in Boston, MA on
Tuesday, March 12, 2019 at
8:40 a.m. ET.
- Barclays Global Healthcare Conference in Miami, FL on Thursday,
March 14, 2019 at 1:35 p.m.
ET.
A live webcast will be accessible on the Events page under
the Investors and Media section of the Myovant website
at www.myovant.com. Please connect to the company's website at
least 15 minutes prior to the presentation to ensure adequate time
for any software download that may be required to listen to the
webcast. A replay of the webcast will be available at the same
location for 30 days following the conference.
About Myovant Sciences
Myovant Sciences is a clinical-stage biopharmaceutical company
focused on developing and commercializing innovative therapies for
the treatment of women's health and endocrine diseases. Myovant's
lead product candidate is relugolix, an oral, once-daily small
molecule that acts as a GnRH receptor antagonist. Myovant has
initiated three clinical programs for relugolix consisting of five
international Phase 3 clinical trials, two in women with heavy
menstrual bleeding associated with uterine fibroids (LIBERTY 1 and
2), two in women with pain associated with endometriosis (SPIRIT 1
and 2), and one in men with advanced prostate cancer (HERO).
Myovant is also developing MVT-602, an oligopeptide kisspeptin-1
receptor agonist, that is in Phase 2a development for the treatment
of female infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG granted Myovant an exclusive,
worldwide license to develop and commercialize relugolix
(excluding Japan and certain other Asian countries where
Takeda retains exclusive rights) and an exclusive license to
develop and commercialize MVT-602 in all countries worldwide. Over
time, Myovant intends to expand its development pipeline to include
other potential treatments for women's health and endocrine
diseases. For more information, please visit Myovant's website
at www.myovant.com.
Investor Contact:
Frank
Karbe
Chief Financial Officer
Myovant Sciences, Inc.
investors@myovant.com
Media Contact:
Julie
Normart
Pure Communications
jnormart@purecommunications.com
559.974.3245
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-to-present-at-upcoming-investor-conferences-300806568.html
SOURCE Myovant Sciences